Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
5
×
boston blog main
boston top stories
life sciences
national blog main
san francisco blog main
cancer
clinical trials
national top stories
san francisco top stories
blueprint medicines
cancer drugs
eli lilly
europe blog main
fda
roche
avapritinib
boston
deals
europe top stories
genentech
indiana blog main
indiana top stories
investing
medullary thyroid cancer
non-small cell lung cancer
pralsetinib
selpercatinib
thyroid cancer
amgen
arena pharmaceuticals
black diamond therapeutics
bladder cancer
boulder/denver blog main
boulder/denver top stories
capmatinib
cardiovascular disease
cobimetinib
colorectal cancer
cstone pharmaceuticals
What
cancer
5
×
drug
5
×
medicines
fda
approval
blueprint
ipo
marketing
research
ret
targets
address
approves
biotech
black
candidate
carries
certain
clinic
companies
currently
designed
despite
diamond
eisai
eluded
family
flags
genetic
hardest
higher
hit
hopes
hottest
hunters
incidence
latest
lead
leading
lines
Language
unset
5
×
Current search:
drug
×
biotech
×
unset
×
cancer
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic